Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss.
Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss.
复制标题
DOI：
10.1016/j.jalz.2010.03.014
复制
发表时间：
2010-09
期刊：
影响因子：
--
通讯作者：
Lyketsos CG
中科院分区：
文献类型：
--
作者：
Mielke MM;Haughey NJ;Bandaru VV;Schech S;Carrick R;Carlson MC;Mori S;Miller MI;Ceritoglu C;Brown T;Albert M;Lyketsos CG
基于血液的阿尔茨海默病（AD）生物标志物在成本、侵入性和重复测量的可行性方面优于脑脊液和神经影像学测量。我们之前在一项基于人群的研究中报道了血液神经酰胺与记忆损伤时间的关系。目前的目的是检查血浆神经酰胺是否随阿尔茨海默病的严重程度而变化，并在一年内与认知能力下降和海马体积损失有关。参与者包括25名正常对照（NC）， 17名健忘轻度认知障碍（MCI）和21名早期可能的AD。在基线和一年后进行了全面的神经心理学电池和神经影像学和海马体积测定。等离子体神经酰胺采用hplc -偶联电喷雾串联质谱法测定。MCI中所有饱和神经酰胺在基线时均低于AD，但MCI组的神经酰胺C22:0和C24:0均显著低于NC组和AD组（p<0.01）。AD组与NC组神经酰胺水平无显著差异（p < 0.05）。在任何组中，神经酰胺C22:0和C24:0与认知表现或海马体积之间没有横断面关联。然而，在MCI组中，较高的基线神经酰胺C22:0和C24:0水平可预测一年后认知能力下降和海马体积损失。结果表明，超长链血浆神经酰胺C22:0和C24:0在轻度认知损伤中发生改变，并预测轻度认知损伤受试者的记忆丧失和右侧海马体积损失。这些血浆神经酰胺可能是阿尔茨海默病进展的早期指标。
A blood-based biomarker of Alzheimer disease (AD) would be superior to CSF and neuroimaging measures in terms of cost, invasiveness and feasibility for repeated measures. We previously reported blood ceramides varied in relation to timing of memory impairment in a population-based study. The present objective was to examine whether plasma ceramides varied by AD severity in a well-characterized clinic sample and were associated with cognitive decline and hippocampal volume loss over one year. Participants included 25 normal controls (NC), 17 amnestic Mild Cognitive Impairment (MCI), and 21 early probable AD. A thorough neuropsychological battery and neuroimaging with hippocampal volume determination were conducted at baseline and one year later. Plasma ceramides were assayed at baseline using HPLC-coupled electrospray ionization tandem mass spectrometry. While all saturated ceramides were lower in MCI compared to AD at baseline, Ceramides C22:0 and C24:0 were significantly lower in the MCI group compared to both NC and AD groups (p<0.01). Ceramide levels did not differ (p>0.05) in AD versus NC. There were no cross-sectional associations between ceramides C22:0 and C24:0 and either cognitive performance or hippocampal volume among any group. However, among the MCI group, higher baseline ceramide C22:0 and C24:0 levels were predictive of cognitive decline and hippocampal volume loss one year later. Results suggest that very long-chain plasma ceramides C22:0 and C24:0 are altered in MCI and predict memory loss and right hippocampal volume loss among subjects with MCI. These plasma ceramides may be early indicators of AD progression.
登录
查看更多内容
影响因子：
4.8
作者：
Vetrivel, KS;Cheng, HP;Thinakaran, G
通讯作者：
Thinakaran, G
DOI：
10.1023/b:visi.0000043755.93987.aa
发表时间：
2005-02-01
影响因子：
19.5
作者：
Beg, MF;Miller, MI;Younes, L
通讯作者：
Younes, L
影响因子：
4.8
作者：
Kalvodova, L;Kahya, N;Simons, K
通讯作者：
Simons, K
影响因子：
4.2
作者：
He, Xingxuan;Huang, Yu;Schuchman, Edward H.
通讯作者：
Schuchman, Edward H.
影响因子：
3.3
作者：
Satoi, H;Tomimoto, H;Okazaki, T
通讯作者：
Okazaki, T